Within the types classification, the Orthopedic Regenerative Medicine market is divided into cellular therapies, biologics, and scaffold‑based platforms, each with specific sub‑categories. Cellular therapies include autologous MSCs, allogeneic MSCs, and induced pluripotent stem‑cell (iPSC) derivatives, distinguished by source, expansion methodology, and regulatory pathway; they dominate the market due to their versatility across multiple applications. Biologics comprise platelet‑rich plasma (PRP), growth‑factor cocktails, and exosome formulations, offering off‑the‑shelf solutions that complement or substitute cellular products. Scaffold‑based platforms consist of natural polymers (collagen, hyaluronic acid), synthetic polymers (PLGA, PCL), and hybrid composites, designed to provide structural support and controlled release of bioactive agents. The relative contribution of each type is reflected in investment trends, with cellular therapies commanding the highest revenue share, biologics expanding rapidly in outpatient settings, and scaffolds gaining traction as delivery vehicles that enhance therapeutic efficacy across the application spectrum.